Merck Gilead Patent Suit: Maker Of Hepatitis C Drugs Harvoni And Sovaldi Ordered To Pay $2.54B In Royalties By Delaware Jury
December 17, 2016
Gilead Sciences Inc. has been ordered to pay Merck & Co. $2.54 billion in royalties in a patent lawsuit over Gilead’s blockbuster hepatitis C drugs Sovaldi and Harvoni.
A federal court jury in Delaware found Thursday Merck’s patent, originally issued to Idenix Pharmaceuticals, a company Merck bought in 2014, was valid and that Gilead “willfully” infringed on it. The lawsuit was filed by Idenix in 2013.